Market Research Report
Global Inflammatory Bowel Disease Treatment Market Size study, by By Type, By Drug Class By Route of Administration, By Distribution Channel and Regional Forecasts 2021-2027
|Global Inflammatory Bowel Disease Treatment Market Size study, by By Type, By Drug Class By Route of Administration, By Distribution Channel and Regional Forecasts 2021-2027|
Published: November 7, 2021
Bizwit Research & Consulting LLP
Delivery time: 2-3 business days
Global Inflammatory Bowel Disease Treatment Market is valued approximately USD 19.2 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 4.8 % over the forecast period 2021-2027. The term Inflammatory Bowel Disease is used for mainly two conditions Crohn's disease and ulcerative colitis. Increase in prevalence of Crohn's disease and ulcerative colitis is the key factor driving the market of inflammatory bowel disease treatment. According to the Crohn's and Colitis Foundation (CCFA), approximately 70,000 fresh cases of inflammatory bowel disease are investigated in the U.S. every year. As per the CCFA report of 2019, about 1.6 million cases were diagnosed in U.S with Inflammatory Bowel Disease. In Europe there were approximately 3.4 billion people were found with any form of IBD in 2020, according to the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA). Growing population of affected people are rising the demand for effective treatment options. Increasing permissions for biosimilars such as Hyrimoz, Imraldi, Renflexis, and Inflectra is projected to increase the adoption of effective treatment due to its advantages over traditional treatment methods. However, high cost of treatment is predicted to impede the growth of the market over the forecast period of 2021-2027. Also, increasing geriatric population is likely to increase the market growth during the forecast period.
The regional analysis of global Inflammatory Bowel Disease Treatment Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the dominating region across the world in terms of market share owing to increasing treatment rates, growing prescription of novel drugs, and better reimbursement policies are some factors affecting the market growth in the region. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027. Factors such as growing Crohn's disease and ulcerative colitis in the region, increasing prescription of biosimilars, and rising novel drug approval would create lucrative growth prospects for the Inflammatory Bowel Disease Treatment Market across Asia-Pacific region.
Major market player included in this report are:
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
By Route of Administration:
By Distribution Channel:
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027
Target Audience of the Global Inflammatory Bowel Disease Treatment Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Value-Added Resellers (VARs)
Third-party knowledge providers
List of figures